• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

3v.org

Venture Capital Matters

  • Sponsored Post
    • Make a Contribution
  • Market Reports
  • Technologies
    • Technology Events
    • Startup Jobs
  • Domain Names for Startups
  • About
    • How to raise venture capital
    • How to raise seed funding from angel investors
    • How private equity and venture capital firms operate
    • What is the difference between private equity and VC funding?
    • What technology trends are considered hot among VC firms?
    • What is elevator pitch?
    • What is startup burn rate?
    • Does failure to launch a startup spell the end of the entrepreneur’s ambitions?
    • How to avoid pitfalls in founding a startup
    • Why do startups fail?
    • What are the traits of successful startup founder?
    • What are startup vanity metrics?
    • Why investing in the next generation of women and diverse entrepreneurs is a crucial part to the success of the tech infrastructure
    • Where are VCs seeing opportunity
    • How do startup valuations work?
    • What is startup accelerator?
    • How to scale an early-stage startup team, how much to pay and how to distribute equity
    • Don’t mix business with friendship: when it comes to building a founding team for a startup, this adage may not always apply
    • What is a social unicorn?
    • Secure Your Startup’s Future: The Importance of Succession Planning
  • Contact

Graphite Bio Launches with $45 Million Series A Financing

September 16, 2020 By admin Leave a Comment

Graphite Bio today announced a $45 million Series A financing led by founding investor Versant Ventures, together with Samsara BioCapital. Graphite Bio is a next-generation gene editing company focused on targeted DNA integration to precisely insert genetic payloads to treat a variety of severe diseases. The company was co-founded by pioneers in the fields of gene editing and gene therapy and has a rapidly maturing pipeline with an upcoming IND and several other candidates advancing toward the clinic in the next 12-18 months.

While many existing gene editing and gene therapy approaches are based on knocking out or randomly integrating genes, Graphite Bio is focused on correcting defective genes by high-efficiency site-specific integration of new genetic sequences. This technology has the potential to precisely repair a damaged portion of a gene, completely replace a malfunctioning gene while retaining normal regulatory control, or to insert a wide range of therapeutic genetic cargoes into precise regions of the genome.

In addition, Graphite Bio’s technology has the potential to provide for durable expression while minimizing toxicity from off-target insertions.

“Our flexible, site-specific approach is extremely powerful and could be used to definitively correct the underlying causes of many severe genetic diseases, and also is applicable to broader disease areas,” said Josh Lehrer, M.D., CEO of Graphite Bio. “With backing from Versant and Samsara, we look forward to progressing our novel medicines into the clinic for patients with high unmet needs.”

Dr. Lehrer joined Graphite Bio after six years at Global Blood Therapeutics (NASDAQ:GBT), where he most recently served as chief medical officer. At GBT, he played a key role in the clinical development and 2019 approval of the company’s Oxbryta therapy for sickle cell disease.

A next-generation gene editing platform

CRISPR-Cas9 gene editing has transformed the biotechnology landscape due to its ability to specifically induce double-stranded DNA breaks that can disrupt genes or genetic control regions, leading to novel treatment approaches for a range of diseases. However, it has been challenging to harness CRISPR-Cas9 for the high-efficiency insertion of new genetic cargo.

Graphite Bio’s gene editing platform includes several complementary technologies that enable targeted and permanent DNA integration at very high efficiency. The platform builds on seminal work led by Dr. Danny Dever in the laboratory of Dr. Matt Porteus at Stanford University demonstrating an increase in integration efficiency from less than 1% to greater than 50% across diverse genetic lesions in a wide range of cell types.

“Achieving high-efficiency targeted gene integration has been a critical objective of gene editing for more than 15 years, but only now is this technologically possible,” said Jerel Davis, Ph.D., Managing Director at Versant and a Graphite Bio board member. “As the founding investor of CRISPR Therapeutics, Versant has seen first-hand the rapid evolution of the gene editing field. Our collaboration with Matt Porteus on CRISPR Therapeutics was highly productive. We are thrilled to be working with him on Graphite Bio, alongside Maria Grazia, Josh and Danny.”

The efficiency improvements enable clinically meaningful levels of targeted integration for therapeutic applications. The company’s medicines therefore can replace defective genes, insert genetic cargo into specific loci and significantly limit undesirable, indiscriminate transgene expression.

Graphite Bio founders and operating plans

The company’s scientific founders include:

Matthew Porteus, M.D., Ph.D., Professor of Pediatrics and Stem Cell Transplantation and the Associate Director of Center for Definitive and Curative Medicine at Stanford University. Dr. Porteus is a pioneer in the gene editing field and has been involved in the space for more than 20 years. He is an academic founder of CRISPR Therapeutics, and advisor to a number of companies in the field as well as the FDA. He has advanced several of Graphite Bio’s technologies and programs at his Stanford lab. As a pediatric hematologist, Dr. Porteus treats patients with severe genetic diseases.
Maria Grazia Roncarolo, M.D., Ph.D., Professor in Stem Cell and Regenerative Medicine, Professor of Pediatrics and of Medicine, Director of the Center for Definitive and Curative Medicine, and Co-Director of the Institute for Stem Cell Biology and Regenerative Medicine at Stanford University. She is a global leader and pioneer in gene therapy, having served as the director of the Telethon Institute for Cell and Gene Therapy at the San Raffaele Scientific Institute in Milan. There, she advanced multiple gene therapy products into the clinic. This work ultimately led to the first approved gene therapy, Strimvelis.
Based on progress to date, Graphite Bio expects to commence Phase 1 studies of its first development candidate in early 2021. The company’s lead program specifically corrects the single nucleotide point mutation in the sickle β globin gene. In cells from patients with the disease, Graphite Bio has shown that its gene correction approach efficiently restores healthy hemoglobin protein and eliminates sickle cell hemoglobin.

In addition, Graphite Bio is advancing several other programs to the clinic, each with the potential to lead to a cure for serious unmet needs.

“It is gratifying to see our work on new gene editing approaches being translated into novel therapies,” said Dr. Porteus. “I’m very excited to be working with Versant again on a start-up and I look forward to collaborating with Samsara and the Graphite Bio team to bring a new generation of genetic treatments to patients.”

In connection with the financing, Abe Bassan, Vice President at Samsara BioCapital, and Carlo Rizzuto, Ph.D., Partner at Versant, joined Graphite Bio’s board.

About Graphite Bio
Graphite Bio is a next-generation gene editing company focused on targeted DNA integration to precisely insert genetic payloads to treat a broad range of severe diseases. The company was co-founded by academic pioneers in the fields of gene editing and gene therapy, and is backed by Versant Ventures and Samsara BioCapital. For more information, please visit www.graphitebio.com.

Filed Under: PR

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Primary Sidebar

Market Analysis

China’s Poaching of Water Technologies from the West: A Serious Concern
Market Scenario of China Banning Exports of Rare Earth Materials and Electric Batteries
Navigating Markets through a 4-Dimensional Research Data Model
A Markov Chain-Based Approach for Forecasting Emerging Technologies: An Extended Analysis
Identifying Resilient Stocks Poised for a Strong Comeback Amidst Economic Recovery
China’s Debt Problem: A Looming Crisis
The Future of Travel: A $15.5 Trillion Industry

Market Research Media

The Evolution of RSS Feeds: A Media Analyst’s Perspective
AI-Enhanced 4-Dimensional Market Dynamics Analysis: Unveiling Trends, Segmentation, Behavior, and Evolution through Markov Chain Modeling
Autotutoring Market: Personalized Learning and Technological Innovation at the Forefront
Integration of Generative AI and Large Language Models for Enterprises
The Decline of Chinese Media Under Authoritarian Rule: Economic Implications
Algorithmic Bias in Media Recommendation Systems: Unveiling Challenges and Pursuing Fairness
U.S. Federal IT Market Forecast

Secondary Sidebar

Technologies

Bridging the Semiconductor Workforce Gap: Intel’s Innovative Educational Initiatives
German Government and Bavaria Invest €300M in ams OSRAM Semiconductor Tech
Innovative Ship Concept: Providing Zero-Carbon Nuclear Energy for Defense and Disaster Relief
Linux Foundation Launches OpenTofu: A New Open Source Alternative to Terraform
Introducing the NETGEAR Nighthawk Tri-Band Mesh WiFi 6E System: Exceptional Range and Performance for the Modern Home

Tech Events

Imagine 2023, Edge AI Conference, September 27, 2023, Computer History Museum, Mountain View, California
Microsoft Ignite, November 14-17, 2023, Seattle
Intel® Innovation 2023, September 19-20 2023, San Jose McEnery Convention Center, San Jose, California
Dreamforce 2023, September 12–14, 2023, Moscone Center, San Francisco
AI Hardware & Edge AI Summit, September 12-14, 2023, Santa Clara Marriott, Santa Clara, California

Footer

Recent Posts

  • Techstars and The Ohio State University Partner to Boost Software Startups in Columbus
  • Atlys Secures $12M to Revolutionize Visa Processing and Travel Experience
  • Afterparty Raises $5 Million Funding to Revolutionize Creator-Fan Interactions with Afterparty AI
  • Elevator Pitch: BornIntoLuxury.com (Born Into Luxury)
  • JETRO’s Global Startup Acceleration Program: Fueling Japanese Startups’ Global Expansion
  • Join the Innovation Wave at SPIE Startup Challenge 2024!
  • CertifID Secures $20M in Series B Funding to Combat Rising Wire Fraud in Real Estate
  • floLIVE Secures $47M Series C Funding to Expand Hyperlocal Global Cellular Network and IoT Solutions
  • Lyten, Inc Secures $200 Million in Series B Funding to Advance Revolutionary 3D Graphene Supermaterials
  • NordicNinja Launches €200 Million Fund II to Drive Sustainable Innovation in Europe

Dossier

EspressoCortado.com: The Artistry of Latte
KeywordResearch.org: The Bedrock of SEO
TravelMktg.com – Experiential Travel Marketing & Storytelling
bookselling.net
Unweb.org, your ultimate privacy guardian

Press Media Release

Editorial: The Yom Kippur War and its lessons for today
Navigating the New Media Landscape: From Print to Pixels
Analysis 2023
TravelMktg.com and Government Organizations Unite for Tourism Promotion
Deloitte: Travel Leaders Embrace Automation and Tech as Workforce Challenges Continue to Weigh on Industry

App Coding

Building a simple SMS (Short Message Service) application using SQLite and jQuery
Rust for Mobile Apps
Comparison of Design Principles: Mobile Apps vs. Desktop Software
Viral App Ideas to Code for Massive User Engagement
Common Pitfalls in Agile Development and How to Avoid Them

API Coding

API Coding Opportunities in Headless Web Publishing
AI-Enhanced API Gateway
Building Powerful APIs for Gaming
Building an API Server to Harness the Power of Large Language Models
Quantitative Analysis Criteria for Assessing API Performance and Quality

Copyright © 2022 3v.org

Technologies, Market Analysis & Market Research and Exclusive Domains

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
Cookie SettingsAccept
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT